UNSPSC 51434814: Piclonidine

This classification denotes an antihypertensive agent with the molecular formula C14H17Cl2N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R7P4D56J1Z, chemically known as (+-)-2-(2,6-dichloro-n-(tetrahydro-2h-pyran-2-yl)anilino)-2-imidazoline but generally known as piclonidine, which bears US NIH Compound Identifier 68914. European Medicines Agency schedules Piclonidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09811MIG.

UNSPSC 51434814 Piclonidine, a Commodity code, covers pharmaceutical substances used by state and local emergency services and health programs. Recent solicitations show state and local governments procuring advanced life support medications, generic pharmaceuticals, and over-the-counter products through direct-purchase and cooperative purchasing mechanisms. The City of Tampa and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) represent the primary issuing bodies visible in current market activity, alongside exploratory procurement from the Texas Health and Human Services Commission. Scope includes sealed-bid purchases of specific medication units with strict expiration-date and warranty requirements, multi-state cooperative purchasing agreements for generic and OTC lines distributed through authorized wholesalers, and market-research RFIs to assess direct-to-manufacturer pharmacy programs. Issuing bodies span municipal fire and rescue departments, state health agencies, and multi-jurisdiction cooperative purchasing entities.

Recent activity concentrates in Florida, Minnesota, Oregon, and Texas. The City of Tampa's Purchasing Department posted an IFB (Solicitation 26P00188) for Advanced Life Support Medications on April 24, 2026, with a due date of April 8, 2026, seeking 370 units of Labetalol, 1,810 units of Epinephrine, 330 units of Adenosine, and 1,020 units of Diltiazem with an estimated contract value of $40,000.00 and a Small Local Business Enterprise sheltered-market designation offering a 5 percent bid discount. MMCAP posted an RFP (Solicitation S1070000015802) on January 20, 2026, due March 26, 2026, for generic multi-source pharmaceuticals and OTC products across Minnesota, Oregon, and participating jurisdictions, requiring manufacturer submissions through AmerisourceBergen, Cardinal Health, and Morris & Dickson as authorized wholesalers, with contract effectiveness July 1, 2026. The Texas HHS Commission issued an RFI (HHS0017013) on April 3, 2026, to explore direct-to-manufacturer prescription-fulfillment capabilities, signaling future formalized procurement. All opportunities emphasize FDA compliance, Good Manufacturing Practices certification, Drug Supply Chain Security Act compliance, comprehensive insurance coverage, and Safety Data Sheets submission.